In this report, we cover catalysts from 19 drugs, categorized into approval and data readouts, as well as deals expected to occur in Q2 2026. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. These data points were provided using a combination of Pharmapremia, Norstella’s drug development benchmarking product utilizing Biomedtracker’s LOA data to assist in informed decisions about drug pipeline prioritization, partnerships, and acquisitions, and drug approval data from Biomedtracker.

Like our report? Have any questions or feedback? Please let us know at clientservices@evaluate.com.